A Phase 1 interventional study of Oral Paclitaxel in combination with Encequidar tablet in Metastatic Breast Cancer, sponsored by Health Hope Pharma. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by Health Hope Pharma · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 373 studies testing paclitaxel in Breast Neoplasms — 40 open to participants now, 60 under way, 13 of them phase 3. Paclitaxel · Breast Neoplasms.
Among the 373 studies testing paclitaxel in Breast Neoplasms, this one is the 224th largest by planned enrollment of the 361 interventional ones that give a count, is one of 5 that started in 2026, is one of 38 in phase 1, reaches primary completion later than 30 of the 59 other live ones, and was the 370th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →40 of the 373 studies testing paclitaxel in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Zhejiang Cancer Hospital · Sites in China
Ages 18+
Liu Shu · Sites in China
Ages 18–70 · Women only
RenJi Hospital · Sites in China
Ages 18–70 · Women only
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Women only
Jazz Pharmaceuticals · Sites in United States, Germany, Italy and 1 more country
Ages 18+
By country, each count listing its studies:
Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
373 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 74 · Phase 2 249 · Phase 3 69 · Phase 4 10
First in 1994; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 46 is below the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 60 across the 361 interventional studies. Of the 254 that completed or were terminated, 125 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 373 have an industry lead sponsor. The 10 most frequent:
Health Hope Pharma is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Health Hope Pharma has 3 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
16 of the studies testing paclitaxel in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183126University of Michigan Rogel Cancer CenterPharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer | 2026-11 |
| NCT03125928Fox Chase Cancer CenterClinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer | 2026-12 |
| NCT07283692RenJi HospitalNeoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) | 2026-12 |
| NCT07580833Health Hope PharmaA Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors | 2026-12 |
| NCT05383196Antonio Giordano, MDOnvansertib + Paclitaxel In TNBC | 2026-12-15 |
Add all 16 to your calendar (.ics) → With an account.
Among the 373 studies testing paclitaxel in Breast Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn about the effect of food on absorption of oral Paclitaxel when co- administered with Encequidar tablets in adult patients with tumours.
The main questions it aims to answer are:
Participants will take Encequidar and oral paclitaxcel with a 1-hour space in between, either after an overnight fast of 10hours or after a meal three days in a row. After 10 days participants that received paclitaxel after fasting will receive the same medicine in the same way after a meal and vice versa. Some participants can elect to take part in the third part of the study which involves taking both paclitaxel and encequidar at the same time after a meal.
Participants will
- For parts 1,2 and 3 participants will stay at the clinic from the day before the study starts until day 4 to receive the medicine and participate in checkups and tests. Participants will then visit the clinic on day 6 and 8 for further checkups and tests
Study Design:
This is a randomized, balanced, multidose, 2-period, two-way (i.e., fed versus fasted), crossover design to examine the effect of food on paclitaxel bioavailability when administered as oPac+E to eligible participants. After completion of the two-way cross over periods, a subset of participants will receive concurrent encequidar and oral paclitaxel capsules after a low-fat meal in Period 3, which is a nonrandomized single arm. Following the Food Effect Part, continued treatment will be offered in the Treatment Part of the study for all participants who complete the Food Effect Part.
In the Food Effect Part (two-way crossover), approximately 46 participants will be randomized. After participants have finished Period 2, they will be asked if they feel comfortable entering Period 3. Enrollment of participants into Period 3 will stop after 8 participants have been enrolled. In the Food Effect Part, an unexpected serious adverse reaction that results in death will be used as stopping criteria for safety that will trigger suspension of enrollment to allow for a detailed safety review. Participants who do not participate in Period 3 will enter into the Treatment Part following Period 2. The Food Effect Part will include Screening, Baseline, Treatment, and safety follow-up.
Food Effect Part:
In the Food Effect Part (randomized 2-period, two-way crossover), participants will receive oPac+E in 2 sequences (fed/fasted or fasted/fed) in which encequidar is administered 1 hour before the oral paclitaxel capsules. A treatment of oPac+E consisting of 3 daily doses will be administered on 3 consecutive days in each period. In Period 3, participants will receive concurrent administration of encequidar and oral paclitaxel after a low-fat meal. As patients with metastatic cancer frequently have decreased appetite and may have difficulty eating a high-fat meal, the Food Effect Part will be conducted using the Food and Drug Administration (FDA) recommended low-fat meal as per the FDA Guidance for Industry "Assessing the Effects of Food on Drugs in INDs and NDAs - Clinical Pharmacology Considerations 2022". Participants will be randomized to the sequence under which they will be administered oPac+E following an overnight fast of at least 10 hours. In each period, participants will be housed in the clinic from Day -1 until after collection of the 72-hour PK sample on Day 4. Participants will then return to the clinic for additional PK sample collections at designated time points on Days 6 and 8. There will be a washout of at least 10 days after the last dose between periods to minimize carryover, based on the estimated half-life (43 hours) of paclitaxel. The oral paclitaxel dose should remain unchanged (total mg dose) during the Food Effect Part of the trial. Period 2 may be delayed up to 3 weeks to allow recovery from toxicity which interrupted treatment or up to 4 weeks to allow flexibility to schedule inpatient treatment. A final visit will occur on the last day of PK sampling or up to 2 weeks after the end of PK sampling.
Period 3 will begin at least 10 days after the last dose in Period 2. Participants will be housed in the clinic from Day -1 until after collection of the 72 hours PK sample on Day 4. Participants will then return to the clinic for additional PK sample collections at designated time points on Days 6 and 8. A final visit will occur on the last day of PK sampling or up to 2 weeks after the end of PK sampling. Participants who discontinue prior to completion of the Food Effect Part will be followed for ongoing or new AE/SAEs until 30 days after the last dose or resolution/stabilization. Participants who successfully complete the Food Effect Part will be offered treatment with oPac+E in the Treatment Part of this protocol to further evaluate oPac+E safety.
Treatment Part:
In the Treatment Part, oPac+E will be administered on an empty stomach at a dose of 205 mg/m2/day for 3 consecutive days per week for 3 weeks of a 4-week cycle, a dose and regimen being used in the ongoing oPac+E development program. Participants who experience toxicity may continue treatment with dose modifications (dose reduction, dose delay) as allowed during management of common paclitaxel toxicity, if considered appropriate by the investigator. oPac+E treatment will be discontinued in participants who did not recover within 3 weeks from oral paclitaxel toxicity that interrupted treatment. Participants in the Treatment Part will continue receiving cycles of treatment until they meet protocol-specified discontinuation criteria or the investigator is of the opinion that the participant is no longer benefitting from treatment and enter the safety follow-up. CT scans will be performed for surveillance of disease every 8 weeks. oPac+E treatment will be stopped if there is disease progression. During the safety follow-up, participants will be followed for 30 days after their last dose. A final visit will occur at the last clinic visit or up to 30 days after the last dose administered.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate hematologic status as demonstrated by not requiring granulocyte colony stimulating factor (G-CSF) or transfusion support within 30 days prior to randomization to achieve the following at Screening/Baseline:
Adequate liver function at Screening/Baseline as demonstrated by:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Food Effect study (randomized 2-period, two-way crossover), participants will receive oPac+E in 2 sequences (fed/fasted or fasted/fed) in which encequidar is administered 1 hour before the oral paclitaxel capsules. A treatment of oPac+E consisting of 3 daily doses will be administered on 3 consecutive days in each period 1 and 2. In Period 3, participants will receive concurrent administration of encequidar and oral paclitaxel after a low-fat meal.
Drug: Oral Paclitaxel in combination with Encequidar tablet
The Food Effect study (randomized 2-period, two-way crossover), participants will receive oPac+E in 2 sequences (fed/fasted or fasted/fed) in which encequidar is administered 1 hour before the oral paclitaxel capsules. A treatment of oPac+E consisting of 3 daily doses will be administered on 3 consecutive days in each period 1 and 2. In Period 3, participants will receive concurrent administration of encequidar and oral paclitaxel after a low-fat meal.
Drug: Oral Paclitaxel in combination with Encequidar tablet
Drug pages: Paclitaxel · Hm-30181
Participant is either fasted or fed when taking Oral Paclitaxel in combination with Encequidar tablet
Area under the plasma concentration-time curve (AUC) from 0 to time of last quantifiable concentration (AUC0-t) and AUC from time 0 to infinity (AUC0-INF) of oral paclitaxel when paclitaxel is administered one hour following encequidar.
The bioavailability of oral paclitaxel, measured by AUC0-t and AUC0-INF, will be determined after oral paclitaxel is administered one hour following encequidar dosing under both fed and fasting conditions. AUC0-t will be calculated using trapezoidal rule. AUC0-INF will be calculated as the sum of AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant.
Time frame: Plasma sample collected from pre-dose on Day 1 to Day 8.
Number of participants with treatment emergent adverse events as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.
Safety and tolerability will be evaluated in terms of treatment emergent AEs and serious adverse events. This includes the types, incidence and severity of treatment emergent adverse events, as well as clinically significant abnormal laboratory test results, abnormal physical examination findings, abnormal vital signs, and abnormal electrocardiogram QT interval that emerge after treatment. Clinical and laboratory adverse events will be primarily graded using NCI CTCAE Version 5.0.
Time frame: From screening to the final follow-up visit.
Maximum observed concentration (Cmax) of oral paclitaxel when paclitaxel is administered one hour following encequidar.
The bioavailability of oral paclitaxel, measured by Cmax, will be determined after oral paclitaxel is administered one hour following encequidar dosing under both fed and fasting conditions.
Time frame: Plasma sample collected from pre-dose on Day 1 to Day 8.
AUC0-t and AUC0-INF for oral paclitaxel when administered concomitantly with encequidar
The bioavailability of oral paclitaxel, measured by AUC0-t and AUC0-INF, will be determined after oral paclitaxel and encequidar are administered concomitantly under fed conditions. AUC0-t will be calculated using trapezoidal rule. AUC 0-INF will be calculated as the sum of AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant.
Time frame: Plasma sample collected from predose on Day 1 to Day 8.
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Dec 2026, 7 months later.
Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 7 months is below that.
Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Paclitaxel · Hm-30181
Health Hope Pharma